Abstract
ABSTRACT
Purpose: The purpose of this article is to review the use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in heart failure (HF) treatment considering the HF phenotype and comorbidities, including type 2 diabetes mellitus (DM) and obesity.
Method: A PubMed and Google Scholar literature search was conducted with search terms, HF and GLP-1 RA. Seven pertinent articles were retrieved and served as the basis for this clinical review.
Results: The efficacy of GLP-1 RA therapy in patients with heart failure with reduced ejection fractions (HFrEF) is unclear, with one study showing increased adverse cardiac events including tachyarrhythmias, and others showing significant benefit. Meta-analysis of secondary endpoints from cardiovascular outcome trials (CVOT) showed reduced HF hospitalization in those with DM treated with GLP-1 RAs. GLP-1 RAs showed significant clinical improvement and weight reduction in heart failure with preserved ejection fraction (HFpEF) and obesity.
Conclusion: GLP-1 RAs are an exciting class of medications approved to treat DM and obesity with positive effects on atherosclerotic coronary vascular disease, but an unclear role in HF treatment. Current data suggests a greater role for GLP-1 therapy in those with HFpEF, especially with comorbid obesity. Further research is needed examining GLP-1 RA therapy in HF based on phenotype and presence of comorbidities.
Keywords: Heart failure, Glucagon-like peptide 1 receptor agonist, GLP-1.
Recommended Citation
Schloemann, Lisa Kristen
(2024)
"Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists in the Treatment of Heart Failure,"
SIU Journal of Medical Science Scholarly Works: Vol. 2:
Iss.
2, Article 2.
Available at:
https://opensiuc.lib.siu.edu/jmssw/vol2/iss2/2
Included in
Cardiology Commons, Cardiovascular Diseases Commons, Chemicals and Drugs Commons, Circulatory and Respiratory Physiology Commons, Endocrine System Diseases Commons, Medical Education Commons, Primary Care Commons